CXCL10 activities, biological structure, and source along with its significant role played in pathophysiology of type i diabetes mellitus

Inflammation

Volumn 36, Issue 2, 2013, Pages 364-371

  Ahmadi, Zahra ^a   Arababadi, Mohammad Kazemi ^a   Hassanshahi, Gholamhossin ^a  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

chemokine; CXCL10; type 1 diabetes

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; AUTOIMMUNITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERFERON PRODUCTION; MICROALBUMINURIA; MOLECULAR PATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; RISK FACTOR; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

CHEMOKINE CXCL10; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION; TH1 CELLS;

EID: 84879506375     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9555-1     Document Type: Article

References (76)

1. Bach, J.F.; and L. Chatenoud. 2001. Tolerance to islet autoantigens in type 1 diabetes. Annual Review of Immunology 19: 131-161.
2. Nepom, G.T. 1995. Class II, antigens and disease susceptibility. Annual Review of Medicine 46: 17-25.
3. Arababadi, M.K. 2010. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iranian Journal of Kidney Diseases 4: 302-306.
4. Pitkanen, J.; and P. Peterson. 2003. Autoimmune regulator: from loss of function to autoimmunity. Genes and Immunity 4: 12-21.
5. Kuchroo, V.K.; D.T. Umetsu, R.H. DeKruyff, et al. 2003. The TIM gene family: emerging roles in immunity and disease. Nature Reviews Immunology 3: 454-462.
6. Ueda, H.; J.M. Howson, L. Esposito, et al. 2003. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423: 506-511.
7. Gale, E.A. 2001. The discovery of type 1 diabetes. Diabetes 50: 217-226.
8. Atkinson, M.A.; and G.S. Eisenbarth. 2001. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358: 221-229.
9. Derakhshan, R.; M.K. Arababadi, Z. Ahmadi, et al. 2012. Increased circulating levels of SDF-1 (CXCL12) in type 2 diabetic patients are correlated to disease state but are unrelated to polymorphism of the SDF-1beta gene in the Iranian population. Inflammation 35: 900-904.
10. Ciesielski, C.J.; E. Andreakos, B.M. Foxwell, et al. 2002. TNFalpha-induced macrophage chemokine secretion is more dependent on NF-kappaB expression than lipopolysaccharides-induced macrophage chemokine secretion. European Journal of Immunology 32: 2037-2045.
11. Ohmori, Y.; and T.A. Hamilton. 1995. The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha. Journal of Immunology 154: 5235-5244.
12. Shields, P.L.; C.M. Morland, M. Salmon, et al. 1999. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. Journal of Immunology 163: 6236-6243.
13. Dillman 3rd, J.F.; K.L. McGary, and J.J. Schlager. 2004. An inhibitor of p38 MAP kinase downregulates cytokine release induced by sulfur mustard exposure in human epidermal keratinocytes. Toxicology In Vitro 18: 593-599.
14. Ohmori, Y.; and T.A. Hamilton. 1994. Cell type and stimulus specific regulation of chemokine gene expression. Biochemical and Biophysical Research Communications 198: 590-596.
15. Treacy, O.; A.E. Ryan, T. Heinzl, et al. 2012. Adenoviral transduction of mesenchymal stem cells: in vitro responses and in vivo immune responses after cell transplantation. PLoS One 7: e42662.
16. Ge, M.Q.; A.W. Ho, Y. Tang, et al. 2012. NK cells regulate CD8+ T cell priming and dendritic cell migration during influenza a infection by IFN-gamma and perforin-dependent mechanisms. Journal of Immunology 6: 6.
17. Moodley, K.; C.E. Angel, M. Glass, et al. 2011. Real-time profiling of NK cell killing of human astrocytes using xCELLigence technology. Journal of Neuroscience Methods 200: 173-180.
18. Zeissig, S.; K. Murata, L. Sweet, et al. 2012. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. Nature Medicine. 18(7): 1060-1068.
19. Luster, A.D.; and J.V. Ravetch. 1987. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). The Journal of Experimental Medicine 166: 1084-1097.
20. Hassanshahi, G.; A. Jafarzadeh, Z. Ghorashi, et al. 2007. Expression of IP-10 chemokine is regulated by pro-inflammatory cytokines in cultured hepatocytes. Iranian Journal of Allergy, Asthma, and Immunology 6: 115-121.
21. Hassanshahi, G.; S.S. Patel, A.A. Jafarzadeh, et al. 2007. Expression of CXC chemokine IP-10/Mob-1 by primary hepatocytes following heat shock. Saudi Medical Journal 28: 514-518.
22. Strieter, R.M.; P.J. Polverini, S.L. Kunkel, et al. 1995. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. Journal of Biological Chemistry 270: 27348-27357.
23. Taub, D.D.; A.R. Lloyd, K. Conlon, et al. 1993. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. The Journal of Experimental Medicine 177: 1809-1814.
24. Jinquan, T.; C. Jing, H.H. Jacobi, et al. 2000. CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma. Journal of Immunology 165: 1548-1556.
25. Hassanshahi, G.; A. Jafarzadeh, B. Esmaeilzadeh, et al. 2008. Assessment of NK cells response to hepatocyte derived chemotactic agents. Pakistan Journal of Biological Sciences 11: 1120-1125.
26. Hanaoka, R.; T. Kasama, M. Muramatsu, et al. 2003. A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Research & Therapy 5: R74-R81.
27. Rotondi, M.; L. Chiovato, S. Romagnani, et al. 2007. Role of chemokines in endocrine autoimmune diseases. Endocrine Reviews 28: 492-520.
28. Luster, A.D. 1998. Chemokines - chemotactic cytokines that mediate inflammation. The New England Journal of Medicine 338: 436-445.
29. Liang, P.; L. Averboukh, W. Zhu, et al. 1994. Ras activation of genes: Mob-1 as a model. Proceedings of the National Academy of Sciences of the United States of America 91: 12515-12519.
30. Deng, W.; Y. Ohmori, and T.A. Hamilton. 1994. Mechanisms of IL-4-mediated suppression of IP-10 gene expression in murine macrophages. Journal of Immunology 153: 2130-2136.
31. Ohmori, Y.; and T.A. Hamilton. 1993. Cooperative interaction between interferon (IFN) stimulus response element and kappa B sequence motifs controls IFN gamma- and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter. Journal of Biological Chemistry 268: 6677-6688.
32. Christen, U.; D.B. McGavern, A.D. Luster, et al. 2003. Among CXCR3 chemokines, IFN-gamma-inducible protein of 10 kDa (CXC chemokine ligand (CXCL) 10) but not monokine induced by IFN-gamma (CXCL9) imprints a pattern for the subsequent development of autoimmune disease. Journal of Immunology 171: 6838-6845.
33. Arimilli, S.; W. Ferlin, N. Solvason, et al. 2000. Chemokines in autoimmune diseases. Immunology Reviews 177: 43-51.
34. Kelsen, S.G.; M.O. Aksoy, Y. Yang, et al. 2004. The chemokine receptor CXCR3 and its splice variant are expressed in human airway epithelial cells. American Journal of Physiology. Lung Cellular and Molecular Physiology 287: L584-L591.
35. Lasagni, L.; M. Francalanci, F. Annunziato, et al. 2003. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. The Journal of Experimental Medicine 197: 1537-1549.
36. Bodnar, R.J.; C.C. Yates, and A. Wells. 2006. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circulation Research 98: 617-625.
37. Addison, C.L.; T.O. Daniel, M.D. Burdick, et al. 2000. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR + CXC chemokine-induced angiogenic activity. Journal of Immunology 165: 5269-5277.
38. Bodnar, R.J.; C.C. Yates, M.E. Rodgers, et al. 2009. IP-10 induces dissociation of newly formed blood vessels. Journal of Cell Science 122: 2064-2077.
39. Taub, D.D.; D.L. Longo, and W.J. Murphy. 1996. Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes-SCID mice. Blood 87: 1423-1431.
40. Park, J.W.; M.E. Gruys, K. McCormick, et al. 2001. Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2). Journal of Immunology 166: 3763-3770.
41. Laing, K.J.; and C.J. Secombes. 2004. Chemokines. Developmental and Comparative Immunology 28: 443-460.
42. Wang, X.; T.L. Yue, E.H. Ohlstein, et al. 1996. Interferon-inducible protein-10 involves vascular smooth muscle cell migration, proliferation, and inflammatory response. Journal of Biological Chemistry 271: 24286-24293.
43. Neville, L.F.; F. Abdullah, P.M. McDonnell, et al. 1995. Mob-1 expression in IL-2-induced ARDS: regulation by TNF-alpha. American Journal of Physiology 269: L884-L890.
44. Lloyd, A.R.; J.J. Oppenheim, D.J. Kelvin, et al. 1996. Chemokines regulate T cell adherence to recombinant adhesion molecules and extracellular matrix proteins. Journal of Immunology 156: 932-938.
45. Kanda, N.; and S. Watanabe. 2002. Histamine inhibits the production of interferon-induced protein of 10 kDa in human squamous cell carcinoma and melanoma. The Journal of Investigative Dermatology 119: 1411-1419.
46. Majumder, S.; L.Z. Zhou, P. Chaturvedi, et al. 1998. Regulation of human IP-10 gene expression in astrocytoma cells by inflammatory cytokines. Journal of Neuroscience Research 54: 169-180.
47. Han, B.; and C.D. Logsdon. 1999. Cholecystokinin induction of mob-1 chemokine expression in pancreatic acinar cells requires NF-kappaB activation. American Journal of Physiology 277: C74-C82.
48. Han, B.; and C.D. Logsdon. 2000. CCK stimulates mob-1 expression and NF-kappaB activation via protein kinase C and intracellular Ca(2+). American Journal of Physiology. Cell Physiology 278: C344-C351.
49. Kaplan, G.; A.D. Luster, G. Hancock, et al. 1987. The expression of a gamma interferon-induced protein (IP-10) in delayed immune responses in human skin. The Journal of Experimental Medicine 166: 1098-1108.
50. Romagnani, P.; E. Lazzeri, L. Lasagni, et al. 2002. IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. Journal of the American Society of Nephrology 13: 53-64.
51. Majumder, S.; L.Z. Zhou, P. Chaturvedi, et al. 1998. p48/STAT-1alpha- containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. Journal of Immunology 161: 4736-4744.
52. Kopydlowski, K.M.; C.A. Salkowski, M.J. Cody, et al. 1999. Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. Journal of Immunology 163: 1537-1544.
53. Swaminathan, G.J.; D.E. Holloway, R.A. Colvin, et al. 2003. Crystal structures of oligomeric forms of the IP-10/CXCL10 chemokine. Structure 11: 521-532.
54. Clark-Lewis, I.; I. Mattioli, J.H. Gong, et al. 2003. Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. Journal of Biological Chemistry 278: 289-295.
55. Goldberg, S.H.; P. van der Meer, J. Hesselgesser, et al. 2001. CXCR3 expression in human central nervous system diseases. Neuropathology and Applied Neurobiology 27: 127-138.
56. Christensen, J.E.; A. Nansen, T. Moos, et al. 2004. Efficient T-cell surveillance of the CNS requires expression of the CXC chemokine receptor 3. Journal of Neuroscience 24: 4849-4858.
57. Christen, U.; and M.G. Von Herrath. 2004. IP-10 and type 1 diabetes: a question of time and location. Autoimmunity 37: 273-282.
58. Rhode, A.; M.E. Pauza, A.M. Barral, et al. 2005. Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. Journal of Immunology 175: 3516-3524.
59. Shimada, A.; J. Morimoto, K. Kodama, et al. 2001. Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 24: 510-515.
60. Suzuki, R.; A. Shimada, T. Maruyama, et al. 2003. T-cell function in anti-GAD65(+)diabetes with residual beta-cell function. Journal of Autoimmunity 20: 83-90.
61. Nicoletti, F.; I. Conget, M. Di Mauro, et al. 2002. Serum concentrations of the interferon-gamma-inducible chemokine IP-10/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease. Diabetologia 45: 1107-1110.
62. Shimada, A.; K. Kodama, J. Morimoto, et al. 2003. Detection of GAD-reactive CD4+ cells in so-called "type 1B" diabetes. Annals of the New York Academy of Sciences 1005: 378-386.
63. Itoh, A.; A. Shimada, K. Kodama, et al. 2004. GAD-reactive T cells were mainly detected in autoimmune-related type 1 diabetic patients with HLA DR9. Annals of the New York Academy of Sciences 1037: 33-40.
64. Shigihara, T.; Y. Oikawa, Y. Kanazawa, et al. 2006. Significance of serum CXCL10/IP-10 level in type 1 diabetes. Journal of Autoimmunity 26: 66-71.
65. Shimada, A.; B. Charlton, P. Rohane, et al. 1996. Immune regulation in type 1 diabetes. Journal of Autoimmunity 9: 263-269.
66. Yamada, S.; J. Irie, A. Shimada, et al. 2003. Assessment of beta cell mass and oxidative peritoneal exudate cells in murine type 1 diabetes using adoptive transfer system. Autoimmunity 36: 63-70.
67. Narumi, S.; Y. Tominaga, M. Tamaru, et al. 1997. Expression of IFN-inducible protein-10 in chronic hepatitis. Journal of Immunology 158: 5536-5544.
68. Han, G.D.; H. Koike, T. Nakatsue, et al. 2003. IFN-inducible protein-10 has a differential role in podocyte during Thy 1.1 glomerulonephritis. Journal of the American Society of Nephrology 14: 3111-3126.
69. Morimoto, J.; H. Yoneyama, A. Shimada, et al. 2004. CXC chemokine ligand 10 neutralization suppresses the occurrence of diabetes in nonobese diabetic mice through enhanced beta cell proliferation without affecting insulitis. Journal of Immunology 173: 7017-7024.
70. Frigerio, S.; T. Junt, B. Lu, et al. 2002. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nature Medicine 8: 1414-1420.
71. Vaidya, V.S.; M.A. Niewczas, L.H. Ficociello, et al. 2011. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-d- glucosaminidase. Kidney International 79: 464-470.
72. Kaas, A.; C. Pfleger, L. Hansen, et al. 2010. Association of adiponectin, interleukin (IL)-1ra, inducible protein 10, IL-6 and number of islet autoantibodies with progression patterns of type 1 diabetes the first year after diagnosis. Clinical and Experimental Immunology 161: 444-452.
73. Hanifi-Moghaddam, P.; N.C. Schloot, S. Kappler, et al. 2003. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 52: 1137-1142.
74. Shigihara, T.; A. Shimada, Y. Oikawa, et al. 2005. CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced beta cell proliferation in NOD mice. Journal of Immunology 175: 8401-8408.
75. Schulthess, F.T.; F. Paroni, N.S. Sauter, et al. 2009. CXCL10 impairs beta cell function and viability in diabetes through TLR4 signaling. Cell Metabolism 9: 125-139.
76. Sabbah, E.; K. Savola, P. Kulmala, et al. 1999. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The childhood diabetes in Finland Study Group. Journal of Clinical Endocrinology and Metabolism 84: 1534-1539.